(Q42715686)

5 November 2017

title

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment (English)

1 reference

5 November 2017

1 reference

ChEBI release 2020-05-28

1 reference

9

J H Beijnen

1 reference

5 November 2017

L A Devriese

1

1 reference

5 November 2017

P O Witteveen

2

1 reference

5 November 2017

S Marchetti

3

1 reference

5 November 2017

M Mergui-Roelvink

4

1 reference

5 November 2017

L Reyderman

5

1 reference

5 November 2017

J Wanders

6

1 reference

5 November 2017

A Jenner

7

1 reference

5 November 2017

G Edwards

8

1 reference

5 November 2017

E E Voest

10

1 reference

5 November 2017

J H M Schellens

11

1 reference

5 November 2017

language of work or name

1 reference

26 September 2012

1 reference

Cancer Chemotherapy and Pharmacology

5 November 2017

published in

1 reference

5 November 2017

volume

70

1 reference

5 November 2017

issue

6

1 reference

5 November 2017

page(s)

823-832

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-012-1976-x

5 November 2017

exact match

0 references

cites work

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

Transection of the oesophagus for bleeding oesophageal varices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1976-X

10.1007/S00280-012-1976-X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

5 November 2017

1025009153

0 references

1 reference